• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Uncertain outcomes: adjusting for misclassification in antimalarial efficacy studies.不确定的结果:在抗疟疗效研究中调整分类错误。
Epidemiol Infect. 2011 Apr;139(4):544-51. doi: 10.1017/S0950268810001652. Epub 2010 Jul 12.
2
The perils of PCR: can we accurately 'correct' antimalarial trials?PCR 的风险:我们能准确“纠正”抗疟试验吗?
Trends Parasitol. 2010 Mar;26(3):119-24. doi: 10.1016/j.pt.2009.12.007. Epub 2010 Jan 18.
3
Validation of PCR for detection and characterization of parasitaemia in massive splenomegaly attributed clinically to malaria infection.PCR 检测和寄生虫血症特征分析在临床上归因于疟疾感染的巨脾症中的验证。
Diagn Microbiol Infect Dis. 2011 Jun;70(2):207-12. doi: 10.1016/j.diagmicrobio.2011.01.007. Epub 2011 Mar 12.
4
Asymptomatic recrudescence after artemether-lumefantrine treatment for uncomplicated falciparum malaria: a systematic review and meta-analysis.青蒿琥酯-咯萘啶治疗无并发症恶性疟原虫疟疾后无症状复发:系统评价和荟萃分析。
Malar J. 2020 Dec 9;19(1):453. doi: 10.1186/s12936-020-03520-1.
5
A method of active case detection to target reservoirs of asymptomatic malaria and gametocyte carriers in a rural area in Southern Province, Zambia.赞比亚南方省农村地区针对无症状疟疾和配子体携带者的主动病例检测方法。
Malar J. 2010 Oct 4;9:265. doi: 10.1186/1475-2875-9-265.
6
Distinction of recrudescences from new infections by PCR-RFLP analysis in a comparative trial of CGP 56 697 and chloroquine in Tanzanian children.在坦桑尼亚儿童中进行的CGP 56 697与氯喹对比试验中,通过聚合酶链反应-限制性片段长度多态性分析区分复发感染与新感染。
Trop Med Int Health. 1998 Jun;3(6):490-7. doi: 10.1046/j.1365-3156.1998.00253.x.
7
Robust Algorithm for Systematic Classification of Malaria Late Treatment Failures as Recrudescence or Reinfection Using Microsatellite Genotyping.使用微卫星基因分型将疟疾晚期治疗失败系统分类为复发或再感染的稳健算法
Antimicrob Agents Chemother. 2015 Oct;59(10):6096-100. doi: 10.1128/AAC.00072-15. Epub 2015 Jul 20.
8
Risk associated with asymptomatic parasitaemia occurring post-antimalarial treatment.抗疟治疗后出现无症状寄生虫血症的相关风险。
Trop Med Int Health. 2008 Jan;13(1):83-90. doi: 10.1111/j.1365-3156.2007.01977.x.
9
Achieving universal testing for malaria.实现疟疾的普遍检测。
BMJ. 2016 Feb 4;352:i107. doi: 10.1136/bmj.i107.
10
Considerations on the mechanism of action of artemisinin antimalarials: part 1--the 'carbon radical' and 'heme' hypotheses.青蒿素类抗疟药作用机制的思考:第1部分——“碳自由基”和“血红素”假说
Infect Disord Drug Targets. 2013 Aug;13(4):217-77. doi: 10.2174/1871526513666131129155708.

引用本文的文献

1
Plasmodium falciparum genetic diversity and multiplicity of infection based on msp-1, msp-2, glurp and microsatellite genetic markers in sub-Saharan Africa: a systematic review and meta-analysis.基于 msp-1、msp-2、glurp 和微卫星遗传标记的撒哈拉以南非洲恶性疟原虫遗传多样性和多重感染:系统评价和荟萃分析。
Malar J. 2024 Apr 8;23(1):97. doi: 10.1186/s12936-024-04925-y.
2
msp1, msp2, and glurp genotyping to differentiate Plasmodium falciparum recrudescence from reinfections during prevention of reestablishment phase, Sri Lanka, 2014-2019.2014 - 2019年斯里兰卡预防再感染阶段,采用msp1、msp2和glurp基因分型鉴别恶性疟原虫复发与再感染情况
Malar J. 2024 Jan 27;23(1):35. doi: 10.1186/s12936-024-04858-6.
3
Artemether-lumefantrine efficacy among adults on antiretroviral therapy in Malawi.ART 在马拉维抗逆转录病毒治疗成人中的疗效。
Malar J. 2023 Jan 27;22(1):32. doi: 10.1186/s12936-023-04466-w.
4
Amplicon deep sequencing improves Plasmodium falciparum genotyping in clinical trials of antimalarial drugs.扩增子深度测序提高了抗疟药物临床试验中恶性疟原虫的基因分型。
Sci Rep. 2019 Nov 28;9(1):17790. doi: 10.1038/s41598-019-54203-0.
5
Longitudinal tracking and quantification of individual Plasmodium falciparum clones in complex infections.复杂感染中个体疟原虫克隆的纵向跟踪和定量。
Sci Rep. 2019 Mar 4;9(1):3333. doi: 10.1038/s41598-019-39656-7.
6
Statistical methods to derive efficacy estimates of anti-malarials for uncomplicated Plasmodium falciparum malaria: pitfalls and challenges.统计方法推断抗疟药物治疗无并发症恶性疟原虫疟疾的疗效:陷阱和挑战。
Malar J. 2017 Oct 26;16(1):430. doi: 10.1186/s12936-017-2074-7.
7
Exact inference for the risk ratio with an imperfect diagnostic test.使用不完美诊断测试对风险比进行精确推断。
Epidemiol Infect. 2017 Jan;145(1):187-193. doi: 10.1017/S0950268816002028. Epub 2016 Sep 9.

本文引用的文献

1
Misclassification of drug failure in Plasmodium falciparum clinical trials in southeast Asia.东南亚恶性疟原虫临床试验中药物治疗失败的错误分类。
J Infect Dis. 2009 Aug 15;200(4):624-8. doi: 10.1086/600892.
2
Polymerase chain reaction adjustment in antimalarial trials: molecular malarkey?抗疟试验中的聚合酶链反应调整:分子闹剧?
J Infect Dis. 2009 Jul 1;200(1):5-7. doi: 10.1086/599379.
3
Effects of Plasmodium falciparum mixed infections on in vitro antimalarial drug tests and genotyping.恶性疟原虫混合感染对体外抗疟药物测试及基因分型的影响。
Am J Trop Med Hyg. 2008 Aug;79(2):178-84.
4
Detection of the dihydrofolate reductase-164L mutation in Plasmodium falciparum infections from Malawi by heteroduplex tracking assay.通过异源双链追踪分析法检测马拉维恶性疟原虫感染中的二氢叶酸还原酶-164L突变。
Am J Trop Med Hyg. 2008 Jun;78(6):892-4.
5
Can estimates of antimalarial efficacy from field studies be improved?来自现场研究的抗疟疗效估计值能否得到改进?
Trends Parasitol. 2008 Feb;24(2):68-73. doi: 10.1016/j.pt.2007.11.003. Epub 2008 Jan 7.
6
Impact of transmission intensity on the accuracy of genotyping to distinguish recrudescence from new infection in antimalarial clinical trials.在抗疟临床试验中,传播强度对通过基因分型区分复发与新感染准确性的影响。
Antimicrob Agents Chemother. 2007 Sep;51(9):3096-103. doi: 10.1128/AAC.00159-07. Epub 2007 Jun 25.
7
Uncertainty analysis: an example of its application to estimating a survey proportion.不确定性分析:其在估计调查比例中的应用示例。
J Epidemiol Community Health. 2007 Jul;61(7):650-4. doi: 10.1136/jech.2006.053660.
8
Minority-variant pfcrt K76T mutations and chloroquine resistance, Malawi.马拉维的少数变异型pfcrt K76T突变与氯喹耐药性
Emerg Infect Dis. 2007 Jun;13(6):872-7. doi: 10.3201/eid1306.061182.
9
The use of genotyping in antimalarial clinical trials: a systematic review of published studies from 1995-2005.基因分型在抗疟临床试验中的应用:对1995年至2005年已发表研究的系统评价
Malar J. 2006 Dec 14;5:122. doi: 10.1186/1475-2875-5-122.
10
Estimating true antimalarial efficacy by heteroduplex tracking assay in patients with complex Plasmodium falciparum infections.采用异源双链追踪分析法评估复杂恶性疟原虫感染患者的真正抗疟疗效。
Antimicrob Agents Chemother. 2007 Feb;51(2):521-7. doi: 10.1128/AAC.00902-06. Epub 2006 Nov 20.

不确定的结果:在抗疟疗效研究中调整分类错误。

Uncertain outcomes: adjusting for misclassification in antimalarial efficacy studies.

机构信息

Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, NC 27599, USA.

出版信息

Epidemiol Infect. 2011 Apr;139(4):544-51. doi: 10.1017/S0950268810001652. Epub 2010 Jul 12.

DOI:10.1017/S0950268810001652
PMID:20619072
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4829077/
Abstract

Evaluation of antimalarial efficacy is difficult because recurrent parasitaemia can be due to recrudescence or re-infection. PCR is used to differentiate between recrudescences and re-infections by comparing parasite allelic variants before and after treatment. However, PCR-corrected results are susceptible to misclassification: false positives, due to re-infection by the same variant present in the patient before treatment; and false negatives, due to variants that are present but too infrequent to be detected in the pre-treatment PCR, but are then detectable post-treatment. This paper aimed to explore factors affecting the probability of false positives and proposes a Monte Carlo uncertainty analysis to account for both types of misclassification. Higher levels of transmission intensity, increased multiplicity of infection, and limited allelic variation resulted in more false recrudescences. The uncertainty analysis exploits characteristics of study data to minimize bias in the estimate of efficacy and can be applied to areas of different transmission intensity.

摘要

疟疾疗效评估较为困难,因为寄生虫血症的再次出现可能是由于疟疾复发或再感染所致。聚合酶链反应(PCR)通过比较治疗前后寄生虫等位基因变体来区分复发和再感染。然而,PCR 校正结果容易发生错误分类:假阳性,是由于治疗前患者体内存在的相同变体再次感染所致;假阴性,是由于治疗前 PCR 检测不到,但治疗后可检测到的存在但频率过低的变体所致。本文旨在探讨影响假阳性概率的因素,并提出一种蒙特卡罗不确定性分析方法来考虑这两种类型的错误分类。较高的传播强度、感染的多发性增加以及等位基因变异有限会导致更多的假复发。不确定性分析利用研究数据的特征,最大限度地减少疗效估计的偏差,可应用于不同传播强度的地区。